Další formáty:
BibTeX
LaTeX
RIS
@article{1218642,
author = {Kiss, Igor and Bortlíček, Zbyněk and Melichar, Bohuslav and Poprach, Alexander and Halámková, Jana and Vyzula, Rostislav and Dušek, Ladislav and Buchler, Tomas},
article_location = {Athens},
article_number = {2},
keywords = {Colorectal cancer; metastasis; bevacizumab; chemotherapy; survival},
language = {eng},
issn = {0250-7005},
journal = {Anticancer Research},
title = {Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma},
volume = {34},
year = {2014}
}
TY - JOUR
ID - 1218642
AU - Kiss, Igor - Bortlíček, Zbyněk - Melichar, Bohuslav - Poprach, Alexander - Halámková, Jana - Vyzula, Rostislav - Dušek, Ladislav - Buchler, Tomas
PY - 2014
TI - Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma
JF - Anticancer Research
VL - 34
IS - 2
SP - 949-954
EP - 949-954
PB - International Institute of Anticancer Research
SN - 02507005
KW - Colorectal cancer
KW - metastasis
KW - bevacizumab
KW - chemotherapy
KW - survival
N2 - The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). Patients and Methods: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 25%) had evaluable data and were included in the present retrospective analysis. Results: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p<0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p<0.001), respectively. Conclusion: The data describe efficacy of bevacizumab with chemotherapy for different treatment lines in a large patient cohort.
ER -
KISS, Igor, Zbyněk BORTLÍČEK, Bohuslav MELICHAR, Alexander POPRACH, Jana HALÁMKOVÁ, Rostislav VYZULA, Ladislav DUŠEK a Tomas BUCHLER. Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, roč.~34, č.~2, s.~949-954. ISSN~0250-7005. 2014.
|
